Publications by authors named "Daniel Booser"

Claim this Profile
R
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance.
Abdelrahman Ali, Efstratios Koutroumpakis, Juhee Song, Daniel Booser, Carlos H Barcenas

JACC CardioOncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study.
Clinton Yam, Miral Patel, Holly A Hill, Ryan Sun, Roland L Bassett, Daniel J Booser

Cancer Res Commun· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention.
Fatma Nihan Akkoc Mustafayev, Diane D Liu, Angelica M Gutierrez, John E Lewis, Nuhad K Ibrahim, Daniel J Booser

Eur J Breast Health· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Blessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, Neeta Somaiah, Sarina Piha-Paul, Daniel J Booser

Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
Bora Lim, Rashmi K Murthy, Jangsoon Lee, Summer A Jackson, Toshiaki Iwase, Daniel J Booser

Br J Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SET: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer.
Bruno V Sinn, Chunxiao Fu, Rosanna Lau, Jennifer Litton, Tsung-Heng Tsai, Daniel Booser

NPJ Breast Cancer· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.
Clinton Yam, Rashmi K Murthy, Gaiane M Rauch, James L Murray, Ronald S Walters, Daniel J Booser

Invest New Drugs· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.
Rashmi K Murthy, Ankur Varma, Priyankana Mishra, Kenneth R Hess, Elliana Young, Daniel Booser

Cancer· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases.
Karen Eckmann, Laura B Michaud, Edgardo Rivera, Timothy L Madden, Laura Esparza-Guerra, Daniel J Booser

J Oncol Pharm Pract· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer.
Windy Dean-Colomb, Kenneth R Hess, Elliana Young, Terrie G Gornet, Beverly C Handy, Daniel Booser

Breast Cancer Res Treat· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy.
Heath D Skinner, Eric A Strom, Sabin B Motwani, Wendy A Woodward, Marjorie C Green, Daniel J Booser

Radiat Oncol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
Libero Santarpia, Yuan Qi, Katherine Stemke-Hale, Bailiang Wang, Elliana J Young, Daniel J Booser

Breast Cancer Res Treat· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results.
Banu K Arun, Kapil Dhinghra, Vicente Valero, Shu-Wan Kau, Kristine Broglio, Daniel Booser

Oncologist· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.
Stacy Moulder, Gregory Gladish, Joe Ensor, Ana Maria Gonzalez-Angulo, Massimo Cristofanilli, Daniel Booser

Cancer· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.
Takayuki Iwamoto, Daniel Booser, Vicente Valero, James L Murray, Kimberly Koenig

J Clin Oncol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.
Catherine M Kelly, Marjorie C Green, Kristine Broglio, Eva S Thomas, Abenaa M Brewster, Daniel J Booser

J Clin Oncol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
Phuong K Morrow, Gerburg M Wulf, Joe Ensor, Daniel J Booser, Julia A Moore

J Clin Oncol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer.
Stacy Moulder, John Moroney, Thorunn Helgason, Jennifer Wheler, Daniel Booser

J Clin Oncol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
Christos Hatzis, Lajos Pusztai, Vicente Valero, Daniel J Booser, Laura Esserman

JAMA· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
Takayuki Iwamoto, Giampaolo Bianchini, Daniel Booser, Yuan Qi, Charles Coutant

J Natl Cancer Inst· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic index of sensitivity to endocrine therapy for breast cancer.
W Fraser Symmans, Christos Hatzis, Christos Sotiriou, Fabrice Andre, Florentia Peintinger, Daniel J Booser

J Clin Oncol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors.
Vlad Popovici, Weijie Chen, Brandon G Gallas, Christos Hatzis, Weiwei Shi, Daniel Booser

Breast Cancer Res· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
Ricardo H Alvarez, Daniel J Booser, Massimo Cristofanilli, Aysegul A Sahin, Eric A Strom

Cancer· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.
Gabriel N Hortobagyi, William Heim, Laura Hutchins, Edgardo Rivera, Bernard Mason, Daniel J Booser

Cancer· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer.
Naoto T Ueno, Jonas A de Souza, Daniel Booser, Kazutaka Nakayama, John Madewell

Clin Breast Cancer· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis